FTEAA
FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research[1][2].
Product Specifications
UNSPSC
12352005
Target
Monoamine Oxidase
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/fteaa.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=C(NC2=CC=C(F)C=C2)CC(C3=CC=C(C(F)(F)F)C=C3)N(C4=CC=C(F)C=C4)C1C5=CC=C(C(F)(F)F)C=C5)OCC
Molecular Formula
C34H26F8N2O2
Molecular Weight
646.57
References & Citations
[1]Schwartz TL, et al. A neuroscientific update on monoamine oxidase and its inhibitors. CNS Spectr. 2013 Dec;18 Suppl 1:25-32; quiz 33. |[2]Bilal AK, et al. Exploring Highly Functionalized Tetrahydropyridine as a Dual Inhibitor of Monoamine Oxidase A and B: Synthesis, Structural Analysis, Single Crystal XRD, Supramolecular Assembly Exploration by Hirshfeld Surface Analysis, and Computational Studies. ACS Omega. 2022 Aug.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MAO-A; MAO-B
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
